Sugi Predict

Sugi Predict / Compounds / SCHEMBL5408845

SCHEMBL5408845

SCHEMBL5408845

COC(=O)[C@H](Cc1ccc(OC)cc1)NC(=O)OC(C)(C)C

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 1/20 0.57
▸ PPARA Q07869 1/20 0.57
▸ KLK5 Q9Y337 1/20 0.57
▸ ITGB3 P05106 1/20 0.55
▸ ITGA2B P08514 1/20 0.55
▸ CACNA1B Q00975 2/20 0.53
▸ CTSS P25774 6/20 0.52
▸ CTSK P43235 5/20 0.52
▸ CTSL P07711 1/20 0.51
▸ CTSB P07858 1/20 0.51
▸ HDAC8 Q9BY41 1/20 0.50
▸ ACE P12821 1/20 0.49
▸ ALDH1A1 P00352 2/20 0.48
▸ LMNA P02545 2/20 0.48
▸ MEN1 O00255 1/20 0.48
▸ KMT2A Q03164 1/20 0.48
▸ LDHA P00338 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5408855 1.00 PPARG (0.57) PPARGPPARAKLK5ITGB3ITGA2B
SCHEMBL13402356 0.95 PPARG (0.57) PPARGPPARAKLK5ITGB3ITGA2B
SCHEMBL17553141 0.95 PPARG (0.57) PPARGPPARAKLK5ITGB3ITGA2B
SCHEMBL30892064 0.92 KLK5 (0.53) PPARGPPARAKLK5ITGB3ITGA2B
SCHEMBL31461514 0.92 ITGB3 (0.51) PPARGPPARAKLK5ITGB3ITGA2B
SCHEMBL19234857 0.92 FPR2 (0.55) PPARGPPARAKLK5ITGB3ITGA2B
SCHEMBL3149446 0.91 PPARG (0.54) PPARGPPARAKLK5ITGB3ITGA2B
SCHEMBL13933239 0.91 ABCB1 (0.57) PPARGPPARAKLK5ITGB3ITGA2B
SCHEMBL13252035 0.91 ABCB1 (0.57) PPARGPPARAKLK5ITGB3ITGA2B
SCHEMBL16463914 0.90 KLK5 (0.53) PPARGPPARAKLK5ITGB3ITGA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119859146-A Gamma-lactam podophyllotoxin compound and preparation method and application thereof 河南农业大学 2025-04-22 — — CN disclosed
WO-2025032242-A1 COMPOUNDS AND USES UNIVERSITEIT LEIDEN (NL) 2025-02-13 — — WO disclosed
EP-4425181-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE Bertis Inc (KR) 2024-09-04 — — EP disclosed
US-20240011979-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTES BERTIS INC. (KR) 2024-01-11 — — US disclosed
EP-3377474-B1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS RQX PHARMACEUTICALS INC (US) 2023-08-16 — — EP disclosed
US-20230144324-A1 PCSK9 ANTAGONIST COMPOUNDS MERCK SHARP & DOHME LLC 2023-05-11 — — US disclosed
US-20230133667-A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS RQX PHARMACEUTICALS INC (US) 2023-05-04 — — US disclosed
US-20230133817-A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS RQX PHARMACEUTICALS INC (US) 2023-05-04 — — US disclosed
WO-2023075435-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE 주식회사 베르티스 2023-05-04 — — WO disclosed
US-20220283131-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTES BERTIS CO., LTD. (KR) 2022-09-08 — — US disclosed
US-20140142029-A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS RQX PHARMACEUTICALS, INC. (US) 2014-05-22 — — US disclosed
WO-2014056748-A1 KETOAMIDE IMMUNOPROTEASOME INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2014-04-17 — — WO disclosed
US-7202269-B2 GlyT2 modulators JANSSEN PHARMACEUTICA N.V. (BE) 2007-04-10 — — US disclosed
WO-2005056543-A2 PROCESS FOR USE IN THE PREPARATION OF OXIRANES FROM ALKENES, AND CATALYSTS FOR USE THEREIN AVECIA PHARMACEUTICALS LIMITED (GB) 2005-06-23 — — WO disclosed
US-20050119245-A1 GlyT2 modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2005-06-02 — — US disclosed
WO-2005044810-A1 GLYT2 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2005-05-19 — — WO disclosed
US-6867333-B2 EPOTHILONE SYNTHESIS BUILDING BLOCKS III AND IV: ASYMMETRICALLY SUBSTITUTED ACYLOINS AND ACYLOIN DERIVATIVES, METHODS FOR THEIR PRODUCTION AND METHODS FOR THE PRODUCTION OF EPOTHILONES B, D AND EPOTHILONE DERIVATIVES MORPHOCHEM AG (DE) 2005-03-15 — — US disclosed
EP-0415981-A4 RETROVIRAL PROTEASE INHIBITORS — 1991-10-09 — — EP disclosed
EP-0415981-A1 RETROVIRAL PROTEASE INHIBITORS ABBOTT LABORATORIES (US) 1991-03-13 — — EP disclosed
WO-1989010752-A1 RETROVIRAL PROTEASE INHIBITORS ABBOTT LABORATORIES (US) 1989-11-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119245-A1 GlyT2 modulators GLRB, GLRA1, GLRA2 PPARG 712/4885PPARA 1271/4885KLK5 4382/4885
US-20140142029-A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS MRPL21, PEPD, CTSC PPARG 3948/4885PPARA 3021/4885KLK5 2545/4885
US-20230133817-A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS MRPL21, PEPD, CTSC PPARG 3948/4885PPARA 3021/4885KLK5 2545/4885
US-20230144324-A1 PCSK9 ANTAGONIST COMPOUNDS PCSK9, PCSK7, PCSK6 PPARG 1396/4885PPARA 850/4885KLK5 129/4885
US-20230133667-A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS MRPL21, PEPD, CTSC PPARG 3948/4885PPARA 3021/4885KLK5 2545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.